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CDK9-mediated transcription elongation
is required for MYC addiction
in hepatocellular carcinoma
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One-year survival rates for newly diagnosed hepatocellular carcinoma (HCC) are <50%, and unresectable HCC
carries a dismal prognosis owing to its aggressiveness and the undruggable nature of its main genetic drivers. By
screening a custom library of shRNAs directed toward known drug targets in a genetically defined Myc-driven
HCC model, we identified cyclin-dependent kinase 9 (Cdk9) as required for disease maintenance. Pharmacological
or shRNA-mediated CDK9 inhibition led to robust anti-tumor effects that correlated with MYC expression levels
and depended on the role that both CDK9 and MYC exert in transcription elongation. Our results establish CDK9
inhibition as a therapeutic strategy for MYC-overexpressing liver tumors and highlight the relevance of
transcription elongation in the addiction of cancer cells to MYC.
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Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related mortality worldwide (Villanueva
et al. 2013). A major risk factor for HCC, the most
common type of primary liver cancer, is cirrhosis, fre-
quently caused by chronic viral hepatitis, alcohol abuse,
and nonalcoholic fatty liver disease (Farazi and DePinho
2006). Although treatment of HCC has greatly improved
over the last decades, most HCC patients diagnosed at
advanced stages are ineligible for curative ablative thera-
pies such as liver resection or transplantation (Villanueva
et al. 2013). The use of the multikinase inhibitor sorafenib
in patients with advanced HCC suggests that targeted
therapies could be beneficial in this cancer; however, this
regimen only extends life expectancy from 8 to 11 mo
(Llovet et al. 2008), highlighting the urgent need for new
therapeutic approaches.
Recent developments in gene expression profiling tech-
nologies have enabled the molecular classification of
HCCs into defined subclasses, creating a solid foundation
onwhich to buildmore informative clinical trials (Hoshida
et al. 2009). Furthermore, exhaustive genomic studies have
identifiedMYC genomic amplifications, b-cateninmuta-
tions, and tumor suppressor TP53 inactivation as frequent
events in HCC (Laurent-Puig et al. 2001; Okamoto et al.
2003). However, unlike other tumor types, which present
genetic drivers that can be therapeutically exploited, such
as EGFRmutations in lung cancer and BRAFmutations in
melanoma (Lynch et al. 2004; Flaherty et al. 2010), HCC is
genetically heterogeneous and lacks clearly targetable
mutant drivers (Villanueva et al. 2013). Thus, it seems
likely that more insights into the function of currently
‘‘undruggable’’ genetic lesions will be necessary to develop
rational therapies for this disease.
The MYC oncoprotein is an example of a well-vali-
dated but currently undruggable driver in HCC. MYC
overexpression induces aberrant proliferation by affecting
different biological processes, including gene transcrip-
tion, protein translation, and DNA replication (Zhang
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et al. 2009; Conacci-Sorrell et al. 2014). Sustained MYC
activation in mice creates a state of oncogene addiction,
while MYC withdrawal in established tumors, including
liver carcinomas, leads to tumor involution (Shachaf et al.
2004; Soucek et al. 2008). Additionally, owing to its role
in mediating oncogenic signals, MYC is required for the
maintenance of some tumors in which it is not amplified,
including murine lung adenomas driven by KRAS and
leukemia driven by MLL-AF9 (Zuber et al. 2011b; Soucek
et al. 2013). In principle, the identification of critical
molecules and processes required forMYC action in cancer
provides an alternative strategy for targeting MYC-driven
tumors (Dawson et al. 2011; Delmore et al. 2011; Zuber
et al. 2011c).
RNAi technology enables a systematic interrogation of
genes whose loss of function affects cell proliferation and
viability (Ashworth and Bernards 2010; Kessler et al.
2012; Kumar et al. 2012). While a powerful method for
identifying novel therapeutic targets, genome-wide RNAi
screens can be laborious and expensive, requiring sub-
stantial infrastructure and specialized expertise for their
execution. For these reasons, we favor focused shRNA
libraries targeting a manageable set of genes with bio-
logical properties predicted to be important for the de-
sired phenotype. Accordingly, we generated a customized
shRNA library capable of suppressing proteins for which
small molecule inhibitors are available; consequently, any
validated hit in the screen should have a chemical probe
to explore the underlying biology and serve as a basis for
developing pharmacological approaches for modulating
the phenotype. By screening the ‘‘drug target’’ library
in a murine HCC model driven by Myc overexpression
and p53 loss, we identified cyclin-dependent kinase 9
(Cdk9), a key component of the positive transcription
elongation factor b (P-TEFb) complex, as required for the
aberrant proliferation of MYC-overexpressing tumors.
Our studies establish CDK9 as a target for a subset of
HCC tumors and document a critical role for transcrip-
tion elongation in sustaining the proliferation of MYC-
overexpressing cancers.
Results
RNAi screen for genes encoding known drug targets
To systematically probe candidate drug targets required for
HCCmaintenance, we developed a screening platform and
a focused shRNA library to facilitate the identification of
cancer dependencies in a defined genetic context. For our
screening system, we established a murine HCC model
driven byMyc overexpression and p53 loss, whichmimics
two of the most common genetic drivers in human HCC
(Supplemental Fig. 1A,B; Beroukhim et al. 2010; Shibata
and Aburatani 2014). These cells also expressed a reverse
tetracycline transactivator (rtTA3) that enabled efficient
induction of tetracycline-responsive transgenes intro-
duced by retroviral-mediated gene transfer (Supplemental
Fig. 1C,D; for details, see the Supplemental Material). We
envisioned that the use of a murine model produced by
defined genetic drivers would avoid some of the confound-
ing effects created by the unknown and heterogeneous
dependencies occurring in human cancer cell lines.
To identify genes whose protein products can be
targeted by established agents, we built a custom
shRNA library against 442 genes encoding known drug
targets (about six shRNAs per gene) (Fig. 1A; Supple-
mental Table 1). This target list consisted of genes
involved in metabolism, protein modifications, signal
transduction, and macromolecular transport (Fig. 1B) and
was biased for receptors and kinases (Supplemental Fig.
1E). The shRNAs were cloned downstream from a tetra-
cycline-responsive promoter in TRMPV-neo (Fig. 1A),
an inducible expression vector that was previously opti-
mized for negative selection RNAi screens (Zuber et al.
2011a,c).
The library was transduced as one pool in triplicate into
murine Myc;p53/ HCC cells (hereafter MP1 cells)
at low multiplicity of infection (MOI < 1). Transduced
cells were cultured such that, in theory, each shRNAwas
represented in at least 1000 cells throughout the exper-
iment (Fig. 1C). After G418 selection, shRNAs were
induced by addition of doxycycline (dox), and changes
in shRNA representation after 12 d of culture were
quantified using deep sequencing of shRNA guide strands
amplified from genomic DNA of sorted shRNA-express-
ing cells (Fig. 1C). The correlation of normalized shRNA
reads present in the replicates at T0 was close to 1 but
substantially decreased when comparing T0 and T12
within the same replicate, suggesting changes in library
representation associated with shRNA depletion (Fig. 1D;
Supplemental Table 2).
Using the scoring criterion of more than fivefold
average depletion in three independent replicates, 43
shRNAs were strongly depleted (Fig. 1E; Supplemental
Table 3); these included all positive control shRNAs
targeting essential genes (Rpa1, n = 1; Rpa3, n = 5; and
Pcna, n = 1) as well as three shRNAs targeting Myc, the
driving oncogene in our model. For a ‘‘hit’’ to undergo
further analysis, we required that at least two indepen-
dent shRNAs targeting a particular gene were identified
in the primary screen. Genes fulfilling these criteria
included the proteasome component Psmb2 (proteasome
subunit b type 2), the replication factor Mcm6 (mini-
chromosome maintenance complex component 6), and
the transcription elongation factor Cdk9.
CDK9 is required for the proliferation of some HCC
cell lines
As our intent was to identify targets whose inhibition
showed selective anti-proliferative effects in cancer cells,
we validated the positive hits above in theMP1 cells used
in the screen and then filtered out those that showed
a similar effect on nontransformed immortalized mouse
embryonic fibroblasts (iMEFs). shRNAs targeting Rpa3,
an essential gene, and Myc, the oncogenic driver in the
screened MP1 cell line, were used as positive controls;
a Renilla luciferase shRNAwas used as negative control.
All selected shRNAs produced a competitive disadvan-
tage in MP1 cells (Fig. 2A), confirming that the screen
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performance and the selection criteria were sufficient to
remove false positive events. Moreover, each validated
shRNA showed substantial knockdown of the intended
protein, further indicating that the observed phenotypes
were due to on-target effects (Fig. 2B).
shRNAs targeting Mcm6 and Psmb2 inhibited iMEFs
and MP1 cells to a similar extent, suggesting that inhi-
bition of their target proteins was generally lethal, much
like the controlRpa3 shRNA (Fig. 2A,C). In contrast,Cdk9
shRNAs showed a reduced ability to inhibit proliferation
in iMEFs as compared with MP1 cells (Fig. 2A,C; Supple-
mental Fig. 2A), an effect that was similar to the Myc
shRNA and could not be accounted for by differences in
proliferation rates of iMEFs and MP1 cells or in shRNA
knockdown (Fig. 2B,D). Owing to this apparent specificity,
we selected Cdk9 as a candidate for more detailed analysis.
To confirm that the impact of CDK9 inhibition on
cancer cell proliferation was not limited to one experi-
mental HCC line, we studied additional murine and
human cell lines engineered to express rtTA3 to allow
dox-dependent shRNA induction. Control (Renilla and
Myc) and Cdk9 shRNAs were subcloned into miR-E, an
optimized miR-30-based backbone that increases knock-
down efficiency, particularly for those shRNAs with
intermediate potency (Supplemental Fig. 2B,C; Fellmann
et al. 2013). All three experimental murine HCC cell lines
that overexpressed Myc (MP1, MP-CH, and Myc-AL)
were highly sensitive to Cdk9 inhibition, while murine
HCC cells expressing mutant KrasG12D, Hepa1-6 hep-
atoma cells, NIH-3T3 fibroblasts, and iMEFs showed
modest to no sensitivity (Fig. 2E). Similarly, human
HCC cell lines showed a range of responses to human
CDK9 shRNAs, with some being sensitive and others
being more resistant (Fig. 2F; Supplemental Fig. 2D).
Again, these differential responses were independent of
the proliferation rates of various cell lines (Supplemental
Fig. 2E,F) and the extent of CDK9 knockdown (Supple-
mental Fig. 2B,G). In contrast to certain cell types in
which CDK9 inhibition triggers cell death, CDK9 knock-
down did not lead to apoptosis in HCC cells (data not
shown) but primarily affected proliferation (Supplemen-
tal Fig. 2A,D). Together, these results indicate that CDK9
is a critical requirement for the ongoing proliferation of
certain cancer cell lines.
Pharmacological inhibition of CDK9 in HCC cell lines
The overarching rationale for our screening setup was
that validated hits would also be targets of existing small
molecule inhibitors. CDK9 is a member of the CDK
family of serine–threonine kinases that forms the cata-
lytic core of P-TEFb and, in the presence of cyclin T,
stimulates transcription elongation by RNA polymerase
II (RNA Pol II) (Peterlin and Price 2006). Many small
molecule drugs initially designed to target other CDKs
also target CDK9, and it is now recognized that CDK9
inhibition contributes to their anti-proliferative effects
(Wang and Fischer 2008). However, molecular determi-
Figure 1. RNAi screen for genes encoding
known drug targets. (A) Library features and
schematic of the TRMPV-neo vector. (B) Path-
way categories of ‘‘drug target’’ genes included
in the library. Numbers indicate the number of
genes in each category. All shRNA sequences
are provided in Supplemental Table 1. (C) RNAi
screening strategy. (D) Representative scatter
plots illustrating the correlation of normalized
reads per shRNA between replicates at the
beginning of the experiment (left) and replicates
at different time points (right) (related to Sup-
plemental Table 2). (E) Pooled negative selec-
tion screening results in MP1 (Myc;p53/
clone 1 murine HCC cells) murine HCC cells.
After eliminating underrepresented shRNAs at
T0 (beginning of the experiment), shRNA abun-
dance ratios of 2246 shRNAs were calculated as
the number of normalized reads after 12 d of
culture on dox (T12, end) divided by the num-
ber of normalized reads before dox treatment (T0)
and are plotted as the mean of three replicates in
ascending order.
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nants that dictate sensitivity to CDK9 inhibition are not
well established, and the potential toxicities of various
nonspecific CDK inhibitors have produced uncertainty as
to whether CDK9 is a cancer-specific therapeutic target.
Nonetheless, our studies using RNAi argue that selective
inhibition of CDK9 can have potent and specific anti-
cancer effects.
Although all currently available CDK9 inhibitors ex-
hibit multiple off-target effects, we hypothesized that
those that are most specific in inhibiting CDK9 would be
the most likely to show a spectrum of activity similar to
CDK9 shRNAs. We therefore examined the growth in-
hibitory effects of several CDK9 inhibitors and compared
the IC50 of each drug with the anti-proliferative effects of
CDK9 shRNAs in competitive proliferation assays (as in
Fig. 2E,F). After testing four different CDK9 inhibitors
(Supplemental Fig. 3A; Wang and Fischer 2008), we found
that PHA-767491, a dual CDK9 and CDC7 (cell division
cycle 7) kinase inhibitor (Montagnoli et al. 2008), most
closely recapitulated shRNA-mediated CDK9 inhibition
in both human and murine cell lines (Fig. 3A–C; Supple-
mental Fig. 3B–D). Notably, CDC7 in complexes with its
allosteric regulator, DBF4, is required for initiation of
DNA replication (Jiang et al. 1999). However, exposure of
cells to aphidicolin, an inhibitor of DNA polymerase, did
not mimic the effects of CDK9 shRNAs (Fig. 3A; Supple-
mental Fig. 3B). In contrast, shRNAs directed to Cyclin
T1 (CCNT1), an obligate allosteric regulator of the CDK9
kinase, recapitulated the results obtained with CDK9
shRNAs (Fig. 3D), thereby highlighting the specificity of
our results.
We evaluated the effect of PHA-767491 in additional
human HCC cell lines (Fig. 3B,C) and observed broad
anti-proliferative activity in the most sensitive cell lines
(IC50 < 2 mM) (Fig. 3E; Supplemental Fig. 3E). PHA-767491
treatment triggered cell cycle arrest, similar to the effects
of CDK9 shRNAs (Fig. 3E; Supplemental Figs. 2D, 3E);
however, the anti-proliferative effects mediated by PHA-
767491 were more pronounced. Of note, BJ, IMR90, and
AML12 (a mouse liver 12), three nontransformed cell
lines, were consistently less sensitive to PHA-767491
treatment (Fig. 3B,C; Supplemental Fig. 3C,D), further
supporting increased sensitivity of certain cancer cells to
CDK9 inhibition. While some of these phenotypes may
be due to CDC7 inhibition (Supplemental Fig. 3A), the
significant correlation between the IC50 of PHA-767491
and the anti-proliferative effects of CDK9 shRNAs im-
plies that a major component of PHA-767491 activity is
through CDK9 inhibition. These data illustrate how
using RNAi and small molecule inhibitors as orthogonal
approaches can assist target validation and indicate that
CDK9 can be required for HCC proliferation.
Figure 2. CDK9 is required for the prolifera-
tion of some HCC cell lines. (A) Competitive
proliferation assay. G418-selected Venus+ cells
were mixed with untransduced cells at 1:1 ratio
and subsequently cultured in the presence of
dox. The percentage of Venus+dsRed+ (shRNA-
expressing) cells was determined at different
time points (results at day 0 and day 14 are
shown and are relative to day 0). Changes were
used as readout of growth inhibitory effects.
Values are mean + SD of three independent
experiments. The graphs show the validation of
the candidate shRNAs as well as control
shRNAs (Ren.713, Myc.1891, and Rpa3.561) in
MP1 murine HCC cells. (B) Immunoblots
showing the knockdown induced by shRNAs
expressed from TRMPV-neo in MP1 murine
HCC cells. b-Actin was used as loading control.
The numbers indicate protein levels relative to
b-actin. (C) Competitive proliferation assay of
control and candidate shRNAs expressed from
TRMPV-neo in iMEFs, as described in A. Color
code is as in A. (D) Immunoblots showing the
knockdown induced by shRNAs expressed
from TRMPV-neo in iMEFs. b-Actin was used
as loading control. The numbers indicate pro-
tein levels relative to b-actin. (E,F) Competitive
proliferation assay of control (Renilla and MYC)
and CDK9 shRNAs expressed from TRMPV-
neo-miR-E (E) or TRMPV-neo (F) in different
murine (E) and human (F) cell lines, as described
in A. The percentage of shRNA-expressing cells
at day 14 relative to day 0 is shown. Values are
mean + SD from two independent experiments.
MYC depends on transcription elongation
GENES & DEVELOPMENT 1803
 Cold Spring Harbor Laboratory Press on September 8, 2014 - Published by genesdev.cshlp.orgDownloaded from 
MYC expression predicts response to CDK9 inhibition
Since our screening system was driven by p53 loss and
Myc overexpression, we next asked whether alterations in
either gene could dictate sensitivity to CDK9 inhibition.
We cross-referenced our data on the relative sensitivity
of HCC cell lines to CDK9 inhibition (measured as the
growth inhibitory effects ofCDK9 shRNAs in competitive
proliferation assays or the IC50 of PHA-767491) to muta-
tional and gene expression profiles of the same cell lines
available from the Cancer Cell Line Encyclopedia (CCLE)
(Barretina et al. 2012). We found no correlation between
the anti-proliferative response to CDK9 inhibition and p53
expression or mutational status (Supplemental Fig. 4A,B),
consistent with previous findings indicating that PHA-
767491 inhibits cancer cell proliferation through p53-
independent mechanisms (Montagnoli et al. 2008).
In contrast, there was a highly significant correlation be-
tween the response to CDK9 inhibition and MYC mRNA
expression (Fig. 4A,B; Supplemental Table 4), an effect
confirmed by immunoblotting for MYC protein (Fig. 4C;
Supplemental Fig. 4C). A similar trendwas noted inmurine
cell lines, further reinforcing these observations (Supple-
mental Fig. 4D). This significant correlation was not
limited to HCC cell lines but was also observed in a panel
of lung and hematopoietic cancer cell lines available in our
laboratory (Fig. 4A; Supplemental Fig. 4E). In all instances,
no correlation was observed between sensitivity to CDK9
inhibition and the relative proliferative rates of individual
cell lines (Supplemental Fig. 4F). Furthermore, no correla-
tion was observed between sensitivity to CDK9 and
sorafenib, a multikinase inhibitor that is the only drug
that confers a significant, albeit limited, survival benefit to
HCC patients (Llovet et al. 2008), or JQ1, a bromodomain
inhibitor known to inhibit MYC in hematological malig-
nancies (Supplemental Fig. 4G; Delmore et al. 2011; Zuber
et al. 2011c). Accordingly, the sensitivity of HCC cells to
sorafenib and JQ1 did not correlate with MYC expression
levels (Supplemental Fig. 4H).
The transcriptional profiles of the 10 human HCC cell
lines with defined sensitivities to PHA-767491 were also
subjected to gene set enrichment analysis (GSEA) and
gene ontology (GO) analysis to point toward genes and
processes thatmight underlie their differential sensitivity
to CDK9 inhibition. This analysis revealed a significant
correlation between low IC50 (sensitivity to CDK9 inhibi-
tion) and four canonical transcriptional signatures ofMYC-
dependent genes (Fig. 4D; Supplemental Table 5; Coller
et al. 2000; Schuhmacher et al. 2001; Zeller et al. 2003;
Schlosser et al. 2005). MYC is a global regulator of gene
expression that affects overall transcription, ribosomal
biogenesis, protein translation, and cellular metabolism
(Dang 2012; Conacci-Sorrell et al. 2014), and, interest-
ingly, transcripts overrepresented in sensitive compared
with resistant cells were linked to ‘‘gene expression,’’
‘‘RNA metabolic process,’’ and ‘‘RNA processing’’ (Fig.
4E; Supplemental Table 6). Taken together, these results
indicate that CDK9 might be crucial for the maintenance
of MYC-overexpressing tumors and identify a potential
patient population whose tumors might be responsive to
CDK9 inhibition.
CDK9 mediates transcription elongation of MYC
targets in MYC-overexpressing cancer cells
After transcription initiation, RNA Pol II is trapped near
the promoter of many genes, a process known as proximal
promoter pausing (Core et al. 2008; Zhou et al. 2012; Lee
and Young 2013). For productive transcription, P-TEFb is
Figure 3. Pharmacological inhibition of CDK9 in HCC cell
lines. (A) Scatter plot illustrating the correlation between anti-
proliferative effects of CDK9 shRNAs and the IC50 of PHA-
767491 in six human cell lines (from Fig. 2F). The correlation
and P-values of three additional CDK9 inhibitors and one DNA
replication inhibitor (aphidicolin) are also shown in the right
panel. The survival is defined as the average of the survival ratio
of two shRNAs in competitive proliferation assay. (FLV) Flavo-
piridol; (PHA) PHA-767491; (SNS) SNS-032; (APHI) aphidicolin. (B)
Proliferation rates of PHA-767491-treated human cells, calcu-
lated by measuring the change in viable cell number after 72 h
in culture and fitting data to an exponential growth curve.
Results were normalized to the proliferation rate of vehicle
(H2O)-treated cells, set to 1. Values are mean 6 SD of three
independent replicates. (C) Summary of PHA-767491 IC50
values of human cell lines in B. (D) Scatter plot illustrating the
correlation between survival with CDK9 shRNAs and survival
with CCNT1 shRNAs in murine and human cell lines (from Fig.
2E,F). (E) Representative flow cytometry plots showing cell cycle
analysis (BrdU+7-AAD+ double staining) of cells after 48 h of
PHA-767491 treatment. The experiment was performed twice,
and values indicate the mean 6 SD.
Huang et al.
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recruited, and CDK9 phosphorylates Ser2 in the C-terminal
domain (CTD) of RNA Pol II, inducing pause release and
subsequent transcription elongation (Zhou et al. 2012; Lee
and Young 2013). MYC has previously been shown to
participate in transcription elongation by regulating this
pause release mechanism (Eberhardy and Farnham 2001;
Kanazawa et al. 2003; Rahl et al. 2010). Hence, in MYC-
overexpressing tumor cells, MYC accumulates in the
promoter region of many transcriptionally active genes,
recruiting the P-TEFb complex and amplifying transcrip-
tion ofMYC target genes (Lin et al. 2012b; Nie et al. 2012).
To explore the role of CDK9 inMYC-mediated transcrip-
tion elongation in HCC, we first investigated the effects of
CDK9 inhibition in two humanHCC cell lines, HepG2 and
Alexander, which express different levels of MYC (Fig. 4C;
Supplemental Table 4). As expected, pharmacological or
RNAi-mediated suppression of CDK9 led to a decrease in
Ser2 phosphorylation in both cell lines (Supplemental Fig.
5A). In order to investigate whether these changes corre-
lated with changes in transcription elongation, we calcu-
lated the pausing index or traveling ratio, in which the ratio
of RNA Pol II-binding density in the proximal promoter
region is compared with that in the gene body (Rahl et al.
2010). In HepG2 cells expressing high levels of MYC,
inhibition of CDK9 (using small molecules or shRNAs) or
MYC caused a significant repression of transcription elon-
gation of NPM1 and MCM4, two select MYC targets, and
an increase in their pausing index (Fig. 5A–C; Supplemental
Fig. 5B). However, no changes were observed for BRG1,
whose transcription is not impacted by MYC (Supplemen-
tal Fig. 5C; Rahl et al. 2010). In contrast, in Alexander cells
expressing much lower MYC levels, the pausing index at
the NPM1 andMCM4 genes was already high in untreated
cells and did not change substantially following CDK9 or
MYC inhibition (Fig. 5C; Supplemental Fig. 5B). Accord-
ingly, CDK9 or MYC inhibition reduced mRNA levels of
MYC target genes in HepG2 cells but not Alexander
cells (Fig. 5D; Supplemental Fig. 5D).
MYC is known to stimulate transcription of trans-
ferrin receptor 1 (TFRC) (Supplemental Fig. 5E,F; O’Donnell
et al. 2006), leading to an increase in steady-state
protein levels. By using 89Zr-desferrioxamine-labeled
transferrin (89Zr-transferrin), a new positron emission
tomography (PET) radiotracer that binds TFRC (Holland
et al. 2012), it is possible to indirectly assess MYC
activity in vivo. HepG2 and Alexander cell lines were
implanted subcutaneously, as the TFRC levels in the
liver are already high via MYC-independent mecha-
nisms (Sciot et al. 1990). Upon tumor formation, mice
were treated with PHA-767491 during 3 d, and PET was
performed 2 d after. PHA-767491 treatment had no effect on
the strong PET signal in the liver and did not change the
signal in low-MYC-expressing Alexander-derived tumors
(Fig. 5E,F; Supplemental Fig. 5G,H). In contrast, PHA-767491
treatment caused a marked decrease in PET signal in the
MYC-overexpressing HepG2 line (Fig. 5E,F; Supplemental
Fig. 5G,H). Together, these results indicate that CDK9
regulates the transcription elongation of several MYC
Figure 4. MYC expression predicts response to
CDK9 inhibition. (A) Scatter plot illustrating
the correlation between PHA-767491 (PHA)
IC50 values and MYC expression levels in
human HCC (red; from Fig. 3B,C), leukemia,
lymphoma, and lung cancer cell lines (n = 28).
(B) Scatter plot illustrating the correlation be-
tween survival with CDK9 shRNAs and MYC
expression levels in a panel of different human
HCC cell lines (from Fig. 2F). The survival is
defined as the average of the survival ratio of
two shRNAs in competitive proliferation assay.
(C) Immunoblots showing MYC protein levels
in 10 human HCC cell lines. b-Actin was used
as loading control. (D) GSEA plot evaluating the
association between low IC50 of PHA-767491
and MYC targets. (NES) Normalized enrich-
ment score; (FDR) false discovery rate. (E) GO
term analysis of the genes that are significantly
associated with sensitivity to PHA-767491.
MYC depends on transcription elongation
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targets in the context of high MYC expression and that
CDK9 inhibition can reverse these effects.
Transcription elongation is required to maintain
proliferation in MYC-overexpressing HCC
MYC has been implicated in DNA replication, transcrip-
tional activation, transcription elongation, and other pro-
cesses (Dang 2012; Conacci-Sorrell et al. 2014), although
the relative contribution of each process to tumor initia-
tion and maintenance is not well understood. Despite the
diversity of factors involved in these processes, we noticed
that CDK9 andMYC shRNAs displayed similar depletion
patterns across multiple lines (Fig. 2E,F), and, in fact, there
was a significant correlation between the anti-proliferative
effects of CDK9 and MYC shRNAs in competitive pro-
liferation assays (Fig. 6A). A similar correlation existed
between the anti-proliferative effects ofCyclin T1 andMyc
shRNAs (Fig. 6B; Supplemental Fig. 6A–C). However, no
correlation was observed between these shRNAs and the
controlRenilla shRNA, confirming the specificity of these
results (Supplemental Table 7).
To directly determine whether modulation of MYC
activity could influence cellular dependence on CDK9,
we tested the ability of enforced MYC expression to
influence sensitivity to CDK9 inhibition. Ectopic MYC
expression in the low-MYC Alexander cells produced
MYC levels;50% of those measured in sensitive HepG2
cells and an increase in MYC-dependent transcription
elongation as measured by a reduced pausing index at the
NPM1 and MCM4 but not BRG1 genes (Fig. 6C,D;
Supplemental Fig. 6D). This effect on transcription elon-
gation was accompanied by significant increases in
NPM1 and MCM4 mRNAs (Fig. 6E; Supplemental Fig.
6E), while levels of BRG1mRNA did not change (Fig. 6E).
Concordantly, MYC-overexpressing Alexander cells be-
came more sensitive to CDK9 inhibition by PHA-767491
or CDK9 shRNAs (Fig. 6F; Supplemental Fig. 6F). While
enforced MYC expression in these cells did not produce
the same sensitivity of high-MYC-expressing HepG2
cells, enforced MYC expression in SNU-475 cells
achieved MYC levels equivalent to those observed in
HepG2 cells (Fig. 6C) and produced a similar sensitivity to
PHA-767491 (Fig. 6F,G), underscoring that high MYC
expression levels are required to establish sensitivity
to CDK9 inhibition. Conversely, MYC suppression in
HepG2 and SNU398 cells, but not Alexander cells, de-
Figure 5. CDK9 mediates transcription
elongation of MYC targets in MYC-
overexpressing cancer cells. (A,B) Chromatin
immunoprecipitation combined with quanti-
tative PCR (ChIP-qPCR) performed in human
HCC cells expressing CDK9 and MYC
shRNAs (A) or treated with PHA-767491
(PHA; 6 h at 4.5 mM) (B), with RNA Pol II
antibody and primers located in either the
transcription start site (TSS) or the gene body
(GB) of NPM1. RNA Pol II occupancy relative
to control condition in HepG2 cells is shown.
Values are mean + SD from two independent
experiments. (C) Pausing index of NPM1 in
human HCC cell lines. The pausing index,
also known as traveling ratio, was calculated
as the ratio between the RNA Pol II bound to
the TSS and the RNA Pol II bound to the GB.
Values are mean + SD from two independent
experiments. Color code and statistics are as
in A and B. (D) Quantitative RT–PCR of
NPM1 in human HCC cell lines treated with
PHA-767491 (16 h at 4.5 mM) or with CDK9
shRNAs. Data are relative to expression in
the untreated cells or Renilla-shRNA in
HepG2 cells, normalized to the average ex-
pression of the housekeeping gene GAPDH.
Values are mean + SD from two independent
experiments. Color code and statistics are as
in A and B. (E,F) PET imaging with 89Zr-
transferrin of HepG2 (E) or Alexander (F)
tumors with or without 3-d treatment with
PHA-767491. (L) Liver; (T) tumor; (trans.)
transverse. The color scale for all PET image
data shows radiotracer uptake in units of
injected dose per gram (%ID/g), with red
corresponding to the highest activity, and
blue corresponding to the lowest activity.
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creased their sensitivity to PHA-767491; however, as the
MYC shRNAs alone reduce their proliferation rate, we
cannot rule out the possibility that this reduced drug
sensitivity is an indirect effect (data not shown). Taken
together, the phenotypic similarities between MYC inhibi-
tion and CDK9/CCNT1 inhibition point to a key role for
transcription elongation in mediating MYC function in
tumor maintenance.
CDK9 is required for initiation and maintenance
of MYC-overexpressing liver tumors
We also investigated the relevance of Cdk9 on HCC
initiation and progression in vivo. To test the role of
Cdk9 on Myc-driven tumorigenesis, we performed hy-
drodynamic tail vein injections of transposons expressing
Myc and different shRNAs, which are integrated into the
liver following transient expression of transposase from
a recombinant transposon vector (Supplemental Fig. 7A;
Yant et al. 2000). Seven weeks after injection, numerous
tumors were observed in the livers expressing control
shRNA; however, Cdk9 or Myc silencing completely
abrogated tumor formation (Fig. 7A,B), indicating that
Cdk9 is required for Myc-driven tumorigenesis.
To suppress Cdk9 in established tumors, MP1 murine
HCC cells were transduced with Luciferase and dox-
inducible TRMPV-Neo-miR-E constructs containing
Cdk9 shRNAs or control shRNAs (Renilla and Myc)
and were transplanted into the livers of recipient mice
by subcapsular injection (Supplemental Fig. 7B). Upon
detection of a luminescent signal, the animals were
randomized and treated with dox to induce shRNA ex-
pression. Tumors bearing Cdk9 shRNAs exhibited a
prominent decrease in the levels of Ser2 phosphorylation
of RNA Pol II, implying that transcription elongation was
efficiently repressed (Fig. 7C). By day 8, bioluminescent
imaging revealed that mice from the untreated group (no
dox) displayed large hepatic tumors; however, knock-
down of Cdk9 orMyc led to a comparable and significant
delay in tumor growth (Fig. 7D,E; Supplemental Fig. 7C).
Ki67 staining of histological sections revealed that tu-
mors expressing shRNAs for Cdk9 or Myc showed less
proliferation compared with tumors expressing the con-
trol Renilla shRNA (Fig. 7F; Supplemental Fig. 7D).
Therefore, RNAi-mediated suppression of Cdk9 approx-
imates the effect ofMyc inhibition in eliciting anti-tumor
effects in HCC in vivo.
We also examined growth inhibitory effects of pharmaco-
logical CDK9 inhibition in a series of human HCC xeno-
grafts expressing luciferase. Treatment with PHA-767491
(50 mg/kg, twice per day, 5 d per week) or vehicle was
initiated upon detection of bioluminescence. Consistent
with previous findings (Montagnoli et al. 2008), PHA-
767491 treatment was well tolerated in mice (Supplemental
Figure 6. Transcription elongation is required to main-
tain proliferation in MYC-overexpressing HCC. (A,B)
Scatter plot illustrating the correlation between sur-
vival with MYC shRNAs and survival with CDK9
shRNAs (A) or CCNT1 shRNAs (B) in mouse (black)
and human (blue) cell lines (from Fig. 2E,F). The
survival is defined as the ratio of surviving cells in
the competitive proliferation assays. In the case of
CDK9 and CCNT1, the average of the survival of two
different shRNAs was used. (C) Immunoblots showing
the effect of MYC overexpression on Ser2 phosphory-
lation of RNA Pol II in low-MYC-expressing SNU475
and Alexander cells. b-Actin was used as loading
control. Values indicate normalized protein levels,
normalized with b-actin or RNA Pol II and relative to
the levels in HepG2 cells. (D) Pausing index of NPM1
and BRG1 in Alexander cells overexpressing MYC.
Pausing index, also known as traveling ratio, was
calculated as the ratio between the RNA Pol II bound
to the TSS and the RNA Pol II bound to the gene body.
Values are mean + SD from two independent experi-
ments. (E) Quantitative RT–PCR of NPM1 and BRG1 in
Alexander cells overexpressing MYC. Data are relative
to expression in the cells expressing an empty vector,
normalized to the average expression of the house-
keeping gene GAPDH. Values are mean + SD from
two independent experiments. (F) Proliferation rates of
PHA-767491 (PHA)-treated cells in C, calculated by
measuring the increase in viable cell number after 72 h
in culture and fitting data to an exponential growth
curve. Results are normalized to the proliferation rate
of vehicle (H2O)-treated cells, set to 1. Values are mean6
SD of two independent replicates. The IC50 values are included at the right in micromolar (mM). (G) Scatter plot illustrating the correlation
between MYC protein levels and the IC50 of PHA-767491 on the different cell lines (related to C and F).
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Figure 7. CDK9 is required for initiation and maintenance of MYC-overexpressing liver tumors. (A) Dot plot representation of the
number of liver tumors after the hydrodynamic injection of Myc oncogene and the corresponding shRNAs. Bars represent the mean 6
SD of five independent mice. (B) Representative bright-field and fluorescent images of the livers in A. Tumors are positive for GFP. (C)
Immunoblots showing the knockdown induced by Cdk9 shRNAs in two representative tumors. Cdk9 inhibition leads to a decrease in
the levels of phosphorylation of Ser2 of RNA Pol II (pSer2) and mild changes in total RNA Pol II levels (Pol II). b-Actin was used as
loading control. (D) Bioluminescent imaging of representative mice orthotopically transplanted with MP1 (Myc;p53/ murine HCC
clone #1) cells harboring the indicated TRMPV-Neo-miR-E shRNAs 8 d after dox treatment. Dox was administered upon disease onset,
7 d after transplant. (E) Quantification of bioluminescent imaging responses with or without dox treatment. Values are mean + SD of six
independent tumors. (F) Quantification of the number of Ki67-positive cells per field after analyzing three fields per animal and three
animals per condition. Values are mean + SD. (G) Immunoblot showing the effects caused by PHA-767491 in two representative
tumors. PHA-767491 treatment leads to a decrease in the levels of phosphorylation of Ser2 of RNA Pol II (pSer2) and mild changes in
total RNA Pol II levels (Pol II). b-Actin was used as loading control. (H) Bioluminescent imaging of representative mice orthotopically
transplanted with either HepG2 or Alexander HCC cells. PHA-767491 was administered upon disease onset (considered as day 0), 28 d after
transplant. Days 3 and 24 of treatment are shown. (I) Quantification of bioluminescent imaging responses with or without PHA-767491
treatment. Values are mean + SD of seven or eight independent tumors. (J) Quantification of the number of Ki67-positive cells per field after
analyzing three fields per animal and three animals per condition. Values are mean + SD.
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Fig. 7E) and triggered a decrease in Pol II Ser2 phosphor-
ylation in the emerging tumors (Fig. 7G). In high-MYC-
expressing HepG2 cells, PHA-767491 also decreased tumor
cell proliferation, which was associated with substantial
inhibition of tumor growth and even some tumor regres-
sions (Fig. 7H–J; Supplemental Fig. 7F–H). In marked con-
trast, the same treatment of low-MYC-expressingAlexander
cells produced little if any effect (Fig. 7H–J; Supplemental
Fig. 7F–H) despite a detectable decrease in Pol II Ser2
phosphorylation (Fig. 7G). Thus, CDK9 is required for the
maintenance of MYC-overexpressing HCC, implicating
transcription elongation as important for MYC dependency
in vivo.
Discussion
HCC is among the most lethal cancers owing to its
aggressive nature and frequently late detection (Villanueva
et al. 2013). While genome characterization efforts have
identified druggable cancer drivers for manymalignancies,
these studies have yet to provide focus for future HCC
therapies, and it seems likely thatmore functional insights
into the mechanism of action of high-frequency yet not
obviously druggable drivers will be needed to develop ra-
tional therapies for this disease. In this regard, the MYC
oncogene is a well-established driver whose overexpres-
sion is required for the maintenance of murine and human
HCC (Shachaf et al. 2004), although, as a transcription
factor, it has not proven amenable to small molecule
inhibition. Here, we show that MYC sustains malig-
nancy in part through CDK9, thereby supporting the
importance of transcription elongation for MYC action
in HCC and implicating CDK9 and the processes it
controls as rational targets for therapies to treat MYC-
overexpressing cancers.
Our study used experimental RNAi to identify genes
that are selectively required for the proliferation or sur-
vival of cancer cells (Ashworth and Bernards 2010; Kessler
et al. 2012; Kumar et al. 2012). We designed a focused
shRNA library to identify small molecules that could be
repurposed for new applications such as treatment of
HCC. Both RNAi and small molecule screens have limi-
tations,mainly related to distinct types of off-target effects,
but the combination of these orthogonal approaches
enabled us to identify and validate CDK9 as a promising
HCC target despite the use of imperfect reagents. Addi-
tionally, the establishment of a genetically defined murine
HCCmodel appeared to bias the screen toward identifying
dependencies produced by one of the drivers without the
need to extensively screen many cell lines. Underscoring
the utility of this approach, we were able to validate the
screening results in human cancer cell lines with complex
genetic alterations. Similarly focused RNAi screens can be
combined with an existing drug to identify novel thera-
peutic combinations or performed in vivo, where hundreds
of genes or drug targets can be evaluated simultaneously in
a single animal (Schramek et al. 2014).
CDK9 has previously been proposed as a potential
therapeutic target for cancer and other diseases (Cho
et al. 2010; Romano 2013). CDK9 inhibitors such as
flavopiridol, SNS-032, or roscovitine have proven particu-
larly efficient for multiplemyeloma or chronic lymphocytic
leukemia through the down-regulation of anti-apoptotic
genes XIAP and Mcl-1 (Gojo et al. 2002; Hahntow et al.
2004; Chen et al. 2009). Interestingly, these cancer types
are often MYC-driven, although whether this explains
their drug sensitivity is not well established. Nonetheless,
further drug development into novel therapies has been
hampered by lack of specificity of drugs and uncertainty
about which patient population would most likely benefit
from such agents. By performing experiments using RNAi
triggers and small molecules in cells from two different
species, we identified CDK9 as a selective therapeu-
tic target for a subset of HCCs. Because CDK9 is not
evidently mutated in HCC (Barretina et al. 2012), the
sensitivity of liver cancer cells to CDK9 inhibition could
not have been revealed simply through genomic studies
alone.
In HCC cells, CDK9 inhibition mainly inhibits pro-
liferation, although tumor regression is also observed
in vivo. While further studies will be required to un-
derstand the precise mechanism of action, our work
clearly identifies MYC overexpression as a key molec-
ular determinant that dictates sensitivity to CDK9
inhibition. Therefore, we predict that HCCs with high
MYC levels will be most likely to respond to improved
CDK9 inhibitors. Thus, our study identifies a drug
target (CDK9), tool compounds (e.g., PHA-767491),
a patient selection criteria (high MYC), and a pharma-
codynamic marker (Ser2 phosphorylation on the CTD
of Pol II) that will greatly facilitate preclinical and
clinical development of this strategy in both liquid
and solid cancers.
CDK9 constitutes the catalytic core of P-TEFb and
stimulates transcription elongation of most protein-cod-
ing genes (Peterlin and Price 2006). CDK9 kinase activity
is stimulated to phosphorylate the CTD of RNA Pol II
through its association with cyclin Tand, consistent with
a requirement of CDK9 activity for transcription elonga-
tion, cyclin T1 shRNAs phenocopied the effects of CDK9
inhibitors at impairing RNA Pol II Ser2 phosphorylation,
transcription elongation of MYC target genes, and cancer
cell proliferation. In agreement with a role for MYC in
these effects, both MYC and CDK9 shRNAs had similar
effects in all of the above assays. Importantly, these
effects correlated with basal MYC levels; hence, tumor
cells with high MYC expression showmore transcription
elongation on MYC target genes than those with low
MYC levels, and enforced MYC expression in low-MYC
cancer cell lines increases elongation and sensitivity to
the anti-proliferative effects of CDK9 inhibition. Our data
support previous work showing that MYC recruits the
CDK9/P-TEFb complex to specific promoters (Eberhardy
and Farnham 2001; Kanazawa et al. 2003; Rahl et al.
2010), thereby enhancing transcriptional output by stim-
ulating transcript elongation via pause release (Lin et al.
2012b; Nie et al. 2012). As such, the P-TEFb complex is
required for MYC to promote transcription elongation, and,
as shown here, MYC-overexpressing tumor cells appear to
depend on this activity. Interestingly, CDK9 inhibitors seem
MYC depends on transcription elongation
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to primarily affect short-lived mRNAs, such as MYC,
suggesting that MYC deregulation itself may contribute to
the anti-tumor effects by CDK9 inhibition (Lam et al. 2001).
Our studies suggest that CDK9 has a ‘‘synthetic lethal’’
relationship with MYC in that its requirement for cancer
cell proliferation is revealed in the presence of MYC
overexpression (Luo et al. 2009). Analogous cofactors
have also been identified, and some are being developed
as therapeutic targets (Goga et al. 2007; Zuber et al.
2011c; Kessler et al. 2012; Lin et al. 2012a; Toyoshima
et al. 2012). For example, BRD4 was identified as a ther-
apeutic target for acute myeloid leukemia and other blood
cancers by virtue of its ability to sustain MYC transcrip-
tion, and small molecule BRD4 inhibitors show potent
anti-leukemic effects (Dawson et al. 2011; Delmore et al.
2011; Zuber et al. 2011c). Interestingly, BRD4 can either
act to sustain MYC transcription by binding superen-
hancers in the MYC promoter or cooperate with MYC to
stimulate transcription elongation through its ability to
recruit P-TEFb (Bisgrove et al. 2007; Loven et al. 2013).
Nonetheless, what determines sensitivity to BRD4 in-
hibition is not understood, and it seems likely that BRD4
is not required to regulate MYC transcription in all cell
types (Lockwood et al. 2012). Accordingly, Brd4 shRNAs
did not score in a parallel screen using the screened HCC
MP1 cell line (A Lujambio, C-H Huang, and SW Lowe,
unpubl.), and the impact of BRD4 shRNAs and JQ1,
a BRD4 inhibitor, on proliferation were not related to
MYC expression in the human HCC lines studied here.
Still, while CDK9 inhibition broadens the possibilities for
‘‘anti-MYC’’ therapy, its impact is not as great as MYC
inhibition. Perhaps combinatorial therapies using the
multikinase inhibitor sorafenib, a recently developed
covalent CDK7 inhibitor that targets transcription regu-
lation (Kwiatkowski et al. 2014), or those targeting other
MYC activities will synergize with CDK9 inhibition in
producing strong anti-tumor effects.
As one of the first oncogenes identified to actively
contribute to human cancer (Dalla-Favera et al. 1982;
Vennstrom et al. 1982), there has been substantial in-
terest in understanding how MYC drives tumorigenesis
and the consequences of MYC inhibition on tumor
growth (Felsher 2010). Collectively, these studies indicate
thatMYC can influence a wide range of cellular processes
and that tumor cells often become addicted to MYC
activity such that MYC withdrawal or inhibition leads
to marked tumor regression (Shachaf et al. 2004; Soucek
et al. 2008). Interestingly, since MYC can mediate the
oncogenic potential of other driving oncogenes (Zuber
et al. 2011b; Soucek et al. 2013), MYC need not be
a genetically altered driver to produce cancer-specific
dependencies. By establishing an epistatic relationship
between MYC and CDK9 in cancer maintenance, we
demonstrate that CDK9 is a key effector of MYC tumor-
promoting activities. While our results do not exclude the
possibility that other MYC functions also play a role
(Sabo et al. 2014; Walz et al. 2014), they imply that
transcription elongation mediated by MYC is essential
for oncogene addiction and provide a strategy for thera-
peutically targeting this addiction in cancer patients.
Materials and methods
Pooled negative selection RNAi screening
A custom shRNA library focused on 442 drug target genes
was designed using miR30-adapted BIOPREDsi predictions (six
shRNAs per gene) and constructed by PCR-cloning a pool of
oligonucleotides synthesized on 55k customized arrays (Agilent
Technologies) as previously described (Zuber et al. 2011a,c). The
list of genes was obtained from DrugBank (version 2.5; http://
www.drugbank.ca) and was manually curated, excluding ambig-
uous or redundant targets. After sequence verification, 2245
shRNAs (five to six per gene) were combined with several
positive and neutral control shRNAs (n = 20) at equal concen-
trations in one pool.
The library was cloned into TRMPV-Neo and transduced into
Tet-on murine HCC MP1 cells using conditions that predomi-
nantly lead to a single retroviral integration and represent each
shRNA in a calculated number of at least 1000 cells. Transduced
cells were selected for 5 d using 1 mg/mL G418 (Invitrogen); at
each passage, >20million cells weremaintained to preserve library
representation throughout the experiment. After drug selection,
T0 samples were obtained (20 million cells per replicate) and
sorted for Venus+ cells. After 12 d (six passages, T12), ;20 million
shRNA-expressing (dsRed+Venus+) cells were sorted for each
replicate using a FACSAriaII (BD Biosciences). Genomic DNA
from T0 and T12 samples was isolated by two rounds of phenol
extraction using PhaseLock tubes (5 Prime) followed by isopro-
panol precipitation.
Animal studies
All mouse experiments were approved by the Memorial Sloan-
Kettering Cancer Center (MSKCC) Animal Care and Use Com-
mittee (protocol no. 11-06-011). Mice were maintained under
specific pathogen-free conditions, and food and water were pro-
vided ad libitum.
Plasmids
For conditional RNAi experiments, shRNAs were expressed
from the TRMPV-Neo vector from either miR-30 or miR-E
backbones, which have been described previously (and are avail-
able from Addgene, catalog no. 27990, or on request) (Zuber et al.
2011a; Fellmann et al. 2013). To produce Tet-on murine HCC
MP1 cells, liver progenitor cells from p53Loxp/Loxp mice were
transduced with CreER and Myc-IRES-rtTA3. For MYC rescue
experiments, the wild-type human MYC cDNA was subcloned
into MSCV-PGK-Puro-IRES-GFP (MSCV-PIG) (Hemann et al.
2003). For the in vivo experiments, cancer cells were infected
with Luciferase-hygro. Human cell lines were infected with
MSCV-RIEP (MSCV-rtTA3-IRES-EcoR-PGK-Puro) (Zuber et al.
2011b). Knockdown efficiency or overexpression was evaluated
by immunoblotting. shRNA sequences are available in Supple-
mental Tables 1 and 8. The pT3 transposon and pT3-EF1a-Myc
vectors were a kind gift of Dr. Xin Chen, University of California
at San Francisco. To generate the constitutive expression vector
pT3-EF1a (Tschaharganeh et al. 2014), the CpG-free EF1a pro-
moter from pCpGfree-vitroBmcs (InvivoGen) was inserted into
pT3, and a GFP-miR-E fragment was cloned following the EF1a
promoter.
Immunoblotting
Liver tissues and cell pellets were lysed in Laemmli buffer or
protein lysis buffer (200 mM NaCl, 0.2% NP40, 50 mM Tris at
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pH 7.5, 1% Tween20, protease and phosphatases inhibitors)
using a tissue homogenizer. Equal amounts of protein were
separated on 12% SDS–polyacrylamide gels and transferred to
PVDF membranes. The abundance of b-actin was monitored to
ensure equal loading. Images were analyzed using the AlphaView
software (ProteinSimple). Detection in immunoblots was per-
formed using antibodies for CDK9 (Santa Cruz Biotechnology),
MCM6 (Santa Cruz Biotechnology), PSMB2 (Santa Cruz Bio-
technology), b-Actin (AC-15, Sigma), p53 (Leica Biosystems),
MYC (Abcam), CCNT1 (Santa Cruz Biotechnology), phopho-
Ser2 RNA Pol II (Cell Signaling), and RNA Pol II (Santa Cruz
Biotechnology). For Ki67 staining (VP-K451, Vector Laborato-
ries), organ samples were fixed in fresh 4% paraformaldehyde
overnight at 4°C and further subjected to routine histological
procedures for embedding in paraffin. Images were taken on
a Zeiss Axio Imager Z2 system.
Proliferation assays
Competitive proliferation assays using shRNAs in TRMPV-Neo
vector (with miR-30 or miR-E backbone) were performed as
described previously (Zuber et al. 2011c). Proliferation assays for
PHA-767491 were performed in vitro by counting the viable cell
numbers over 72 h in the presence of different PHA-767491
concentrations. Dead cells were excluded using propidium
iodide (PI) staining to score cells with sub-2N DNA content.
Measurements of cell concentration were performed on a Guava
Easycyte (Millipore), gating only viable cells (FSC/SSC/PI).
Proliferation rates were calculated by dividing cell concentration
at 72 h and cell concentration at 0 h, divided by 72. Relative
proliferation rates were calculated by normalizing to the rate of
vehicle-treated cells. Population doublings were calculated by
calculating log2 (cells at end point/cells at initial point) divided
by time in days.
shRNA experiments in human HCC cell lines
HepG2, Hep3B, SKHep1, SNU398, SNU475, and Alexander cells
were modified to express the ecotropic receptor and rtTA3 by
transducing MSCV-RIEP (MSCV-rtTA3-IRES-EcoR-PGK-Puro)
followed by drug selection (1 mg/mL puromycin for 1 wk). The
resulting cell lines were transduced with ecotropically packaged
TRMPV-Neo-shRNA retroviruses with either miR-30 or miR-E
backbone, selected with 1 mg/mL G418 for 1 wk, and treated
with 1 mg/mL dox to induce shRNA expression. The relative
change in Venus+dsRed+ (shRNA+) cells was monitored on
a Guava Easycyte (Millipore) by performing proliferation com-
petitive assays.
Chromatin immunoprecipitation (ChIP)
ChIP assays were performed as previously described (Bracken
et al. 2006). Briefly, cross-linking was performed with 1%
formaldehyde, and cells were lysed in SDS buffer. DNA was
fragmented by sonication (Bioruptor). ChIP for RNA Pol II was
performed using a specific antibody (N-20, Santa Cruz Biotech-
nology). DNA enrichment was measured by quantitative PCR
performed using SYBR Green (ABI) on a ViiA 7 (Life Technolo-
gies). Each reaction was done in triplicate using gene-specific
primers. Each immunoprecipitate signal was referenced to an
input standard curve dilution series (immunoprecipitate/input)
to normalize for differences in starting cell number and for
primer amplification efficiency. Pausing index, also known as
traveling ratio, was calculated as the ratio between the RNA Pol
II bound to the transcription start site and the RNA Pol II bound
to the gene body. The list of ChIP primers is included in
Supplemental Table 9.
Small animal PET imaging
For in vivo assays, human holo-Transferrin was labeled with
89Zr. The 89Zr was prepared as previously described (Holland
et al. 2009). Female athymic nudemice were inoculated with 53
106 to 10 3 106 cells reconstituted in a 1:1 mixture of medium
and Matrigel in the shoulder. After tumors reached ;500 mm3,
mice were treated with PHA-767491 for 3 d and, 2 d after,
injected with 275–300 mCi of 89Zr-holoTransferrin via the tail
vein. At various time points following injection (24–48 h), mice
were scanned using a MicroPET Focus 120 Scanner (Concorde
Microsystems). Approximately 5 min before recording PET
images, mice were anesthetized by inhalation of 1%–2% iso-
flurane (Baxter Healthcare) in an oxygen gas mixture and placed
on the scanner bed. Image reconstruction and processing details
have been reported elsewhere (Holland et al. 2010). For biodis-
tribution studies, mice (n = 5; 10 tumors) were euthanized by
CO2 at 48 h post-injection, and organs were harvested immedi-
ately. The radioactivity in each organ was counted alongside
a known amount of 89Zr, the counts were correlated to activity,
and decay was corrected. The organs were then weighed, and the
percentage of the injected dose per gram (%ID/g) in each tissue
was calculated.
Hydrodynamic tail vein injection
A sterile 0.9% NaCl solution/plasmid mix was prepared con-
taining 5 µg of DNA of pT3-EF1a-Myc and 20 µg of DNA of pT3-
EF1a-GFP-miRe Transposon vector together with CMV-SB13
Transposase (1:5 ratio) for each injection. FVBN mice from JAX
were injected with the 0.9%NaCl solution/plasmid mix into the
lateral tail vein with a total volume corresponding to 10% of
body weight in 5–7 sec.
Statistics
Statistical significance was calculated by two-tailed Student’s
t-test. Correlation was calculated by Pearson test. Prism 5 soft-
ware was used to calculate the IC50 values. Significance values
are P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***).
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